Screen-and-treat program by point-of-care of Atopobium vaginae and Gardnerella vaginalis in preventing preterm birth (AuTop trial): study protocol for a randomized controlled trial

Florence Bretelle, Florence Fenollar, Karine Baumstarck, Cécile Fortanier, Jean François Cocallemen, Valérie Serazin, Didier Raoult, Pascal Auquier, Sandrine Loubière, Florence Bretelle, Florence Fenollar, Karine Baumstarck, Cécile Fortanier, Jean François Cocallemen, Valérie Serazin, Didier Raoult, Pascal Auquier, Sandrine Loubière

Abstract

Background: International recommendations in favor of screening for vaginal infection in pregnancy are based on heterogeneous criteria. In most developed countries, the diagnosis of bacterial vaginosis is only recommended for women with high-risk of preterm birth. The Nugent score is currently used, but molecular quantification tools have recently been reported with a high sensitivity and specificity. Their value for reducing preterm birth rates and related complications remains unexplored. This trial was designed to assess the cost-effectiveness of a systematic screen-and-treat program based on a point-of-care technique for rapid molecular diagnosis, immediately followed by an appropriate antibiotic treatment, to detect the presence of abnormal vaginal flora (specifically, Atopobium vaginae and Gardnerella vaginalis) before 20 weeks of gestation in pregnant women in France. We hypothesized that this program would translate into significant reductions in both the rate of preterm births and the medical costs associated with preterm birth.

Methods/design: A multicenter, open-label randomized controlled trial (RCT) will be conducted in which 20 French obstetrics and gynecology centers will recruit eligible pregnant women at less than 20 weeks gestation with singleton pregnancy and with a low-risk factor for preterm birth. Interventions will include a) an experimental group that will receive a systematic rapid screen-and-treat program from a point-of-care analysis using a molecular quantification method and b) a control group that will receive usual care management. Randomization will be in a 1:1 allocation ratio. The primary endpoint that will be assessed over a period of 12 months will be the incremental cost-effectiveness ratio (ICER) expressed as cost per avoided preterm birth before 37 weeks. Secondary endpoints will include ICER per avoided preterm birth before 24, 28 and 32 weeks, obstetrical outcomes, neonatal outcomes, rates of treatment failure and recurrence episodes for positive women. Uncertainty surrounding these estimates will be addressed using nonparametric bootstrapping and represented using cost-effectiveness acceptability curves. A total of 6,800 pregnant women will be included.

Discussion: This appropriate randomized controlled design will provide insight into the cost-effectiveness and therefore the potential cost savings of a rapid screen-and-treat strategy for molecular abnormal vaginal flora in pregnant women. National and international recommendations could be updated based on the findings of this study.

Trial registration: ClinicalTrials.gov: NCT02288832 (registration date: 30 October 2014); Eudract: 2014-001559-22.

Figures

Fig. 1
Fig. 1
Schema of timing and phasing - AuTop Study
Fig. 2
Fig. 2
Schema of treatment algorithm alongside the trial - AuTop Study

References

    1. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012;379:2151–61. doi: 10.1016/S0140-6736(12)60560-1.
    1. Blondel B, Lelong N, Kermarrec M, Goffinet F. National Coordination Group of the National Perinatal S. Trends in perinatal health in France from 1995 to 2010. Results from the French National Perinatal Surveys. J Gynecol Obstet Biol Reprod (Paris) 2012;41:e1–e15. doi: 10.1016/j.jgyn.2012.04.014.
    1. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379:2162–72. doi: 10.1016/S0140-6736(12)60820-4.
    1. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371:75–84. doi: 10.1016/S0140-6736(08)60074-4.
    1. Leitich H, Kiss H. Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol. 2007;21:375–90. doi: 10.1016/j.bpobgyn.2006.12.005.
    1. Menard JP, Mazouni C, Fenollar F, Raoult D, Boubli L, Bretelle F. Diagnostic accuracy of quantitative real-time PCR assay versus clinical and Gram stain identification of bacterial vaginosis. Eur J Clin Microbiol Infect Dis. 2010;29:1547–52. doi: 10.1007/s10096-010-1039-3.
    1. Cartwright CP, Lembke BD, Ramachandran K, Body BA, Nye MB, Rivers CA, et al. Development and validation of a semiquantitative, multitarget PCR assay for diagnosis of bacterial vaginosis. J Clin Microbiol. 2012;50:2321–9. doi: 10.1128/JCM.00506-12.
    1. Marconi C, Cruciani F, Vitali B, Donders GG. Correlation of Atopobium vaginae amount with bacterial vaginosis markers. J Low Genit Tract Dis. 2012;16:127–32. doi: 10.1097/LGT.0b013e31823c79c4.
    1. Menard JP, Fenollar F, Henry M, Bretelle F, Raoult D. Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial vaginosis. Clin Infect Dis. 2008;47:33–43. doi: 10.1086/588661.
    1. Menard JP, Mazouni C, Salem-Cherif I, Fenollar F, Raoult D, Boubli L, et al. High vaginal concentrations of Atopobium vaginae and Gardnerella vaginalis in women undergoing preterm labor. Obstet Gynecol. 2010;115:134–40. doi: 10.1097/AOG.0b013e3181c391d7.
    1. Bretelle F, Rozenberg P, Pascal A, Favre R, Bohec C, Loundou A, et al. High Atopobium vaginae and Gardnerella vaginalis Vaginal Loads are associated with preterm birth. Clin Infect Dis. 2015;60:860–7. doi: 10.1093/cid/ciu966.
    1. HAS. Prévention anténatale du risque infectieux bactérien néonatal précoce: recommandations, Septembre 2001. In: Servoces recommandations et références professionnelles. 2001. . Accessed 15 April 2015.
    1. Centers for Disease Control and Prevention (CDC). Sexually Transmitted Diseases Treatment Guidelines, 2010. In: Recommendations and Reports. 2010. . Accessed 15 April 2015.
    1. Joesoef MR, Schmid G. Bacterial vaginosis. Clin Evid. 2005;13:1968–78.
    1. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005;353:1899–911. doi: 10.1056/NEJMoa043802.
    1. Shipitsyna E, Roos A, Datcu R, Hallen A, Fredlund H, Jensen JS, et al. Composition of the vaginal microbiota in women of reproductive age--sensitive and specific molecular diagnosis of bacterial vaginosis is possible? PLoS One. 2013;8:e60670. doi: 10.1371/journal.pone.0060670.
    1. Menard JP, Fenollar F, Raoult D, Boubli L, Bretelle F. Self-collected vaginal swabs for the quantitative real-time polymerase chain reaction assay of Atopobium vaginae and Gardnerella vaginalis and the diagnosis of bacterial vaginosis. Eur J Clin Microbiol Infect Dis. 2012;31:513–8. doi: 10.1007/s10096-011-1341-8.
    1. Kiss H, Pichler E, Petricevic L, Husslein P. Cost effectiveness of a screen-and-treat program for asymptomatic vaginal infections in pregnancy: towards a significant reduction in the costs of prematurity. Eur J Obstet Gynecol Reprod Biol. 2006;127:198–203. doi: 10.1016/j.ejogrb.2005.10.017.
    1. AAA, ACOG . Guidelines for perinatal care. American Academy of Pediatrics. American College of Obstetricians and Gynecologists. 7. Washington, DC: Elk Grove Village (IL); 2012.
    1. Beaino G, Khoshnood B, Kaminski M, Marret S, Pierrat V, Vieux R, et al. Predictors of the risk of cognitive deficiency in very preterm infants: the EPIPAGE prospective cohort. Acta Paediatr. 2011;100:370–8. doi: 10.1111/j.1651-2227.2010.02064.x.
    1. Berbis J, Einaudi MA, Simeoni MC, Brevaut-Malaty V, Auquier P, d'Ercole C, et al. Quality of life of early school-age French children born preterm: a cohort study. Eur J Obstet Gynecol Reprod Biol. 2012;162:38–44. doi: 10.1016/j.ejogrb.2012.02.006.
    1. Briggs AH, Gray AM. Power and sample size calculations for stochastic cost-effectiveness analysis. Med Decis Making. 1998;18(2 Suppl):S81–92. doi: 10.1177/0272989X9801800210.
    1. Kiss H, Petricevic L, Husslein P. Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery. BMJ. 2004;329:371. doi: 10.1136/bmj.38169.519653.EB.
    1. Goffinet F, Maillard F, Mihoubi N, Kayem G, Papiernik E, Cabrol D, et al. Bacterial vaginosis: prevalence and predictive value for premature delivery and neonatal infection in women with preterm labour and intact membranes. Eur J Obstet Gynecol Reprod Biol. 2003;108:146–51. doi: 10.1016/S0301-2115(02)00423-2.
    1. Petrou S, Khan K. Economic costs associated with moderate and late preterm birth: primary and secondary evidence. Semin Fetal Neonatal Med. 2012;17:170–8. doi: 10.1016/j.siny.2012.02.001.
    1. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010;11:32. doi: 10.1186/1745-6215-11-32.
    1. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
    1. Clements KM, Barfield WD, Ayadi MF, Wilber N. Preterm birth-associated cost of early intervention services: an analysis by gestational age. Pediatrics. 2007;119:e866–874. doi: 10.1542/peds.2006-1729.
    1. Russell RB, Green NS, Steiner CA, Meikle S, Howse JL, Poschman K, et al. Cost of hospitalization for preterm and low birth weight infants in the United States. Pediatrics. 2007;120:e1–9. doi: 10.1542/peds.2006-2386.
    1. Petrou S. The economic consequences of preterm birth during the first 10 years of life. BJOG. 2005;112(Suppl 1):10–5. doi: 10.1111/j.1471-0528.2005.00577.x.
    1. Briggs AH. Statistical approaches to handling uncertainty in health economic evaluation. Eur J Gastroenterol Hepatol. 2004;16:551–61. doi: 10.1097/00042737-200406000-00007.
    1. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779–87. doi: 10.1002/hec.635.
    1. Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.
    1. Okun N, Gronau KA, Hannah ME. Antibiotics for bacterial vaginosis or Trichomonas vaginalis in pregnancy: a systematic review. Obstet Gynecol. 2005;105:857–68. doi: 10.1097/01.AOG.0000157108.32059.8f.
    1. Nygren P, Fu R, Freeman M, Bougatsos C, Klebanoff M, Guise JM, et al. Evidence on the benefits and harms of screening and treating pregnant women who are asymptomatic for bacterial vaginosis: an update review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;148:220–33. doi: 10.7326/0003-4819-148-3-200802050-00008.
    1. Lamont RF, Taylor-Robinson D. Review of the accuracy of various diagnostic tests for bacterial vaginosis to predict preterm birth (Honest et al., BJOG, May 2004) BJOG. 2005;112:259–60. doi: 10.1111/j.1471-0528.2005.00241.x.
    1. McGregor JA, French JI, Parker R, Draper D, Patterson E, Jones W, et al. Prevention of premature birth by screening and treatment for common genital tract infections: results of a prospective controlled evaluation. Am J Obstet Gynecol. 1995;173:157–67. doi: 10.1016/0002-9378(95)90184-1.
    1. Menard JP, Bretelle F. How can the treatment of bacterial vaginosis be improved to reduce the risk of preterm delivery? Womens Health (Lond Engl) 2012;8:491–3. doi: 10.2217/whe.12.32.
    1. Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193:1478–86. doi: 10.1086/503780.
    1. De Backer E, Verhelst R, Verstraelen H, Claeys G, Verschraegen G, Temmerman M, et al. Antibiotic susceptibility of Atopobium vaginae. BMC Infect Dis. 2006;6:51. doi: 10.1186/1471-2334-6-51.
    1. Svare JA, Schmidt H, Hansen BB, Lose G. Bacterial vaginosis in a cohort of Danish pregnant women: prevalence and relationship with preterm delivery, low birthweight and perinatal infections. BJOG. 2006;113:1419–25. doi: 10.1111/j.1471-0528.2006.01087.x.
    1. Behrman RE, Butler AS. Preterm birth: causes, consequences, and prevention. Washington (DC): National Academies Press (US); 2007.
    1. Mangham LJ, Petrou S, Doyle LW, Draper ES, Marlow N. The cost of preterm birth throughout childhood in England and Wales. Pediatrics. 2009;123:e312–327. doi: 10.1542/peds.2008-1827.
    1. Korvenranta E, Lehtonen L, Rautava L, Hakkinen U, Andersson S, Gissler M, et al. Impact of very preterm birth on health care costs at five years of age. Pediatrics. 2010;125:e1109–1114. doi: 10.1542/peds.2009-2882.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться